2023 World Conference on Lung Cancer (Posters)-EP12.01. Osimertinib in Epidermal Growth Factor Receptor-Mutated (EGFR+) Metastatic Non-Small-Cell Lung Cancer (NSCLC) Real-World Patients

EP12.01. Osimertinib in Epidermal Growth Factor Receptor-Mutated (EGFR+) Metastatic Non-Small-Cell Lung Cancer (NSCLC) Real-World Patients - PDF(Slides)

Back to course

Pdf Summary

A real-world observational study conducted at the Hospital of Leon in Spain evaluated the effectiveness of osimertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI), in the treatment of EGFR-mutated metastatic non-small-cell lung cancer (NSCLC). The study included 46 patients diagnosed with EGFR NSCLC between 2011 and 2022 who received osimertinib either as a first-line or subsequent-line treatment.<br /><br />The study found that the majority of the patients were female (65.2%) and had a median age of 70 years. The most common EGFR mutation type was exon 19 deletion (58.7%), followed by L858R (23.9%). A significant percentage of patients (46%) had brain metastases at the time of diagnosis. Osimertinib was primarily administered as a first-line treatment (52.2%) or a second-line treatment (38.7%).<br /><br />The effectiveness of osimertinib in this patient population was evaluated in terms of response rate, duration of response, progression-free survival, and overall survival. The study reported a response rate of 71.8%, with a median time to response of 10.2 weeks. The median duration of response was 17.3 months, and the median progression-free survival was 20 months. The median overall survival was 33.8 months, with 84% of patients surviving at 12 months, 70% at 24 months, and 46% at 36 months.<br /><br />Adverse events associated with osimertinib included diarrhea (30.4%), rash or acne (34.7%), thrombocytopenia (6.5%), neumonitis (4.3%), hepatitis (2.1%), and arrhythmia (2.1%).<br /><br />Overall, the study demonstrated the effectiveness of osimertinib in the real-world setting for patients with EGFR-mutated advanced NSCLC. These findings provide valuable insights into the use of this third-generation EGFR-TKI beyond the controlled environment of clinical trials.

Asset Subtitle

Blanca Távara

Meta Tag

Speaker Blanca Távara

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

observational study

osimertinib

EGFR-mutated NSCLC

response rate

progression-free survival

overall survival

adverse events

diarrhea

rash

clinical trials